Enterome is a clinical stage company developing off-the-shelf, transformational cancer treatments targeting all tumor types. Ongoing Phase 2 trials for our most advanced programs EO2401 and EO2463 have shown promising efficacy in recurrent glioblastoma, in adrenal tumors and in Non-Hodgkin lymphoma, with good safety in more than 200 patients.
Enterome’s OncoMimics™ approach generates a powerful, long-lasting immune response from the patient’s own effector memory T cells, overcoming the immune tolerance to self-antigens. Watch our video here
With 4 clinical immune-oncology projects to date, our fully integrated R&D platform has the potential to deliver multiple candidates with a rapid progression “from bench to bedside”. In addition to OncoMimics™ programs, Enterome has also established a partnership with Nestlé Health Science in inflammatory diseases and food allergy.